# Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors

> **NCT03081923** · PHASE2 · TERMINATED · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 36 (actual)

## Conditions studied

- Germ Cell Tumor

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT03081923
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-01
- **Primary completion:** 2019-12-06
- **Final completion:** 2019-12-06
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** loss of accrual
- **Last updated:** 2021-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03081923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03081923, "Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03081923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*